News ReleaseView printer-friendly version
Quidel Announces European Patent Decision - German Court Upholds Company's Patent for Immunodiagnostic Device
SAN DIEGO, Feb. 23 /PRNewswire/ -- Quidel Corporation (Nasdaq: QDEL) announced today that the Appeals Board of the European Patent Office, in oral proceedings in Munich, Germany, upheld and validated Quidel's immunodiagnostic patent (0260965). The patent, which was opposed by Abbott Laboratories, covers a device containing a moisture-absorbing desiccant (drying) material housed in a compartment within an assay test strip device. The desiccant extends the shelf life and performance capability of many lateral flow immunodiagnostic products including Quidel's own Pregnancy, Group A Strep, and H. pylori tests.
"The affirmation of this patent is important to Quidel because it covers a production method that places the drying material in the same plastic housing as the test strip and is a very important part of our intellectual property assets," said Andre de Bruin, Vice Chairman and Chief Executive Officer.
A related US patent was issued in 1998 (Immunodiagnostic Device, US patent 5,763,262), which also claims a desiccant material in the same housing with the strip.
Quidel Corporation discovers, develops, manufactures and markets point-of-care, rapid diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions that affect women's health throughout the phases of their lives including reproductive status, pregnancy management and osteoporosis. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia and infectious mononucleosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs, and increase patient satisfaction.
This press release contains forward-looking statements regarding Quidel's future activities within the meaning of the federal securities laws. These forward-looking statements involve material risks and uncertainties. Many possible factors could affect the future results and performance of Quidel's products, such that actual results and performance may differ materially. If Quidel's products fail to perform as expected, or if there is lower consumer demand for these products than expected, Quidel's financial condition and operating results may be materially and adversely affected. Quidel's financial condition and operating results may also be materially and adversely affected by a number of other factors, including, without limitation, seasonality, adverse changes in competitive and economic conditions, actions by the Company's distributors, manufacturing and production delays or difficulties and adverse actions or delays in product reviews by the FDA. Please see the discussion of these and other factors in Quidel's annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. For more information, please visit Quidel's web site at http://www.quidel.com.
Sharon Platt, Investor Relations Associate of Quidel Corporation, 858-552-7955;,br> or Miriam Weber, Vice President of Noonan/Russo Communications, 212-696-4455, ext. 352, for Quidel Corporation